I n recent years, major advances have been made in transcriptomics, metabolomics, proteomics, and particularly population genetics. More than 850 genome-wide association studies (GWAS) were published by the end of 2010, now covering a vast number of diseases and phenotypes and often incorporating tens of thousands of subjects or, in some cases, more than 100 000 subjects, increasing statistical power to identify and replicate contributing loci. Sequencing throughput advances and decreasing costs per sample have allowed the application of genome-wide genotyping and sequencing technology to larger DNA samples as well as transcriptome and epigenome features. This year was marked not only by continuing progress with GWAS, sequencing, and copy number variation studies but also by follow-up of GWAS and other findings with functional studies that uncover new molecular pathways contributing to disease and pave the way for future clinical applications.
The American Heart Association Functional Genomics and Translational Biology Interdisciplinary Council (http://www. americanheart.org/presenter.jhtml?identifierϭ3016539) provides a forum for a multidisciplinary group of volunteers committed to making a substantial contribution to reduce the burden of heart disease and stroke through genetics, genomics, proteomics, and metabolomics research and translational science. With input from the Early Career Committee of the Council on Functional Genomics and Translational Biology, we considered many papers and selected 10 outstanding manuscript groups (15 articles) published in 2010 that reflect these advances, and we briefly summarize each below in chronological order.
Two groups reported deletions of chromosome 16p11.2 that are rare but when present are very often associated with severe obesity. The minimal deletion region contains the SH2B1 gene, which is involved in leptin and insulin signaling and whose disruption in mice results in obesity and insulin resistance. The strategy they used to identify the lesionusing small, well-phenotyped cohorts of extreme phenotypes with targeted follow-up in GWAS and population cohortsshows promise as a means of identifying "missing heritability" in complex disorders more generally. In this study, investigators evaluated 69 discrete peripheral blood metabolites measured by liquid chromatography with mass spectrometry and analyzed related groups of metabolites via principal components analysis for association with coronary artery disease (CAD) and subsequent event risk in individuals undergoing cardiac catheterization for suspected disease. Using discovery and replication samples, Shah et al found and replicated in independent samples the association of several individual metabolites (leucine/isoleucine, glutamate/glutamine, long-chain acylcarnitines) with prevalent CAD, as well as groups of factors (branch-chain amino acid related, urea-cycle related) with CAD and with subsequent cardiovascular events (short-chain dicarboxylacylcarnitines) after median follow-up of 2.7 years. Analyses adjusted for risk factors and potential confounders generally remained significant, and the addition of metabolites to risk models improved the c-statistic (a measure of the discrimination of a model), suggesting metabolites may eventually provide additional predictive information beyond traditional risk factors for prevalent CAD and subsequent events. In this study, the investigators engineered a deletion of the 70 kb noncoding region of the mouse genome that is orthologous to the human 58 kb locus on chromosome 9p21 recently identified in several GWAS as being the most strongly associated with CAD and myocardial infarction. They demonstrated that the deleted region harbors elements that regulate the expression of 2 nearby cell cycle regulators thereby influencing vascular cell proliferation. Although they were not able to definitively establish a link to atherosclerotic vascular disease (mice being a suboptimal model for atherosclerosis), the work represents one of the first attempts at functional validation of a novel GWAS association. Although the utility of including CYP2C9 and VKORC1 genotypes in algorithms to select appropriate starting warfarin doses for patients has been suggested by previous work, the optimal algorithms and application to diverse patient cohorts requires further studies. In the largest and most diverse study to date on warfarin pharmacogenetics, Limdi et al find that in addition to CYP2C9 alleles, 1 VKORC1 single-nucleotide polymorphism allele (alternatively either Ϫ1639A or 1173T) is maximally informative across diverse populations, and little benefit is gained from including additional single-nucleotide polymorphisms. Their findings show that despite allele frequencies differences across worldwide populations, VKORC1 genotype is an important predictor of initial warfarin dose in both European and nonEuropean ancestry populations. Two groups reported a new molecular pathway that regulates the plasma level of high-density lipoprotein, an antiatherogenic lipoprotein that protects against CAD. They identified a microRNA called miR-33 that blocks the secretion of cholesterol from the liver by reducing the expression of the membrane transporter ABCA1. Targeting miR-33 using knockout or antisense strategies rapidly increased plasma high-density lipoprotein cholesterol levels in mice and may prove to be a potent therapeutic strategy to treat metabolic syndrome in humans.
In one of the largest genetic studies to date (sample sizes Ͼ100 000 individuals in some cases), Teslovich et al newly implicate 59 additional loci in plasma lipid concentrations in addition to 36 prior loci and make a number of important advances: (1) their multilocus models now explain a significant proportion of the population genetic variance in lipid concentrations, (2) Mega et al showed in a meta-analysis of 9 studies that 1 or 2 copies of a reduced-function allele of CYP2C19, which encodes a metabolizer of the antiplatelet agent clopidogrel, is associated with increased risk of adverse outcomes of treatment with the drug. In contrast, in a study of 2 other randomized trials, Pare et al found CYP2C19 reduced-function alleles were not associated with outcomes of treatment with clopidogrel. The differences among the studies with respect to CYP2C19 associations may be due to differences in the treated populations, with the populations studied by Mega et al being more aggressively treated (Ͼ90% undergoing percutaneous coronary intervention) relative to those studied by Pare et al (Ͻ20% undergoing percutaneous coronary intervention), highlighting the importance of precisely defining clinical contexts for pharmacogenetic applications. Two papers highlighted the emerging applications of exome sequencing for mendelian and complex disorders. Haack et al reported the first application of whole exome sequencing to identify 1 cause of mitochondrial complex I deficiency, a rare mendelian disorder characterized by hypertrophic cardiomyopathy and lactic acidosis. They showed that mutations in ACAD9 lead to complex I disruption and impair mitochondrial respiration, with validation of the gene by using it to correct the complex I defect in fibroblasts taken from patients with the disease. Johansen et al reported the results of a 2-tiered strategy to identify common and rare variants associated with hypertriglyceridemia: a GWAS of individuals at the extreme end of the hypertriglyceridemia phenotype followed by targeted resequencing of the most promising candidate genes. They demonstrated that 4 genes (APOA5, GCKR, LPL, and APOB) whose common variants were identified in population-based GWAS also harbored an increased frequency of rare coding variants compared with controls. These findings reinforce the concept of a continuum of effects across the allele frequency spectrum and provide a template for future large-scale sequencing efforts. Weerapana et al presented a powerful new method for detecting functional sites on proteins. By tagging proteomes with specific electrophilic reagents at limiting concentrations, they were able to detect a subset of highly reactive cysteines. Their method robustly distinguished which catalytically active residues were essential for enzymatic functions, and it has broad potential applications in basic research and drug development.
